

Newsletter

Updates in the Diagnosis of Meningitis and Encephalitis

Compiled by the Microbiologists

Meningitis presents with some combination of neck stiffness, fever, headache, nausea, vomiting and photophobia. Encephalitis is distinguished from meningitis by the presence of abnormal brain function as evidenced by altered mental status, motor or sensory deficits, altered behaviour or personality changes, and speech or movement disorders. When meningeal and parenchymal involvement both occur, there can be a mixed presentation of meningoencephalitis as is often seen with viral infections. Meningitis may be due to bacterial, mycobacterial, fungal (mainly Cryptococcus neoformans) or viral causes. Encephalitis is most frequently associated with a viral infection.

Acute Bacterial Meningitis

The incidence of acute bacterial meningitis (ABM) has decreased in the last decade due to:

- The introduction of *Haemophilus influenzae* type B and conjugated *Streptococcus pneumoniae* vaccines into childhood vaccination programmes. Recently, a conjugated vaccine against *Neisseria meningitidis* strains A, C, Y, W135 has also become commercially available.
- Screening of pregnant women for *Streptococcus agalactiae* (Group B Strep) as advocated by numerous clinical guidelines, with antibiotic prophylaxis being given to women during delivery to decrease the burden of Group B strep neonatal sepsis.

Despite these interventions, it is estimated that 1.2 million cases of bacterial meningitis occur annually worldwide. Bacterial meningitis has a high morbidity (hearing loss, visual impairment, limb loss and cognitive impairment) and mortality if left untreated. Therefore, appropriate antibiotic treatment for the causative pathogen should be started as quickly as possible.

Table 1. The most common communityacquired organisms responsible for ABM

Adults and children > 6 months of age	Infants < 6 months of age
Streptococcus pneumoniae	Group B Strep
Haemophilus influenzae	Listeria monocytogenes
Neisseria meningitidis	Escherichia coli K1
Listeria monocytogenes (in immunocompromised persons)	



Lancet Laboratories Limited Conservation House - 2nd Floor Along Ali Hassan Mwinyi Road Tel: +255 752 816 904 Email: info@lancet.co.tz www.cerbalancetafrica.co.tz. P.O Box 105894 Dar es Salaam, Tanzania www.cerbalancetafrica.co.tz. customer service.tanzania@lancet.co.tz



Viral Meningoencephalitis

Many different viruses can infect the central nervous system (CNS). Some are more likely to cause meningitis while others are more likely to cause encephalitis, but often there is a mixed presentation with features of both (meningoencephalitis).

Table 2. Causes of viral centralnervous system infections

Herpes viruses:

Herpes simplex virus type 1 and type 2, varicellazoster virus, Epstein-Barr virus, cytomegalovirus, human herpesviruses 6 & 7

Enteroviruses: Includes coxsackie viruses and echoviruses

Parechovirus

Paramyxoviruses: Mumps virus, measles virus

Respiratory viruses: Adenovirus, influenza virus

Arboviruses: West Nile virus, Rift Valley fever virus, dengue virus, chikungunya virus

Human immunodeficiency virus

Rabies virus

Diagnosis

Clinical manifestations of meningitis are relatively non-specific with regards to aetiology and it is difficult to differentiate bacterial from viral causes. Inflammatory markers such as Creactive

protein and procalcitonin are highly suggestive of a bacterial infection, but neither can definitively establish nor exclude the diagnosis of ABM.

Identification of the causative organism is essential for many reasons. Neisseria meningitidis has public health implications, and close contacts of the patient should be identified and given

prophylactic antibiotics. Most of the common organisms responsible for ABM can be treated with Ceftriaxone, except Listeria monocytogenes, which is inherently resistant to the cephalosporin class of antibiotics.

Treatment is available for a number of viral infections of the CNS, most notably HSV-1, HSV-2, and VZV.

Definitive diagnosis involves performing a lumbar puncture (LP), if it is not contraindicated, and

submitting the cerebrospinal fluid (CSF) to the laboratory for analysis. The CSF should be

examined microscopically for cells (polymorphonuclear cells (PMNs), lymphocytes, and red blood cells). Typical changes of ABM include raised PMNs, but lymphocytes may also be raised in early disease, confounding the diagnosis.

Similarly, PMNs may be raised early in viral infections as well.

Chemistry of the CSF in ABM typically demonstrates low glucose compared to serum glucose and high total protein % 0.45 g/mL. Isolation of the organism by culturing the CSF was traditionally the "gold standard" of diagnosis. Some of the organisms responsible for ABM have fastidious culture requirements and the chance of a positive culture also decreases with prior antibiotic treatment. Thus, sensitivity of culture may be low. Streptococcus pneumoniae has autolytic enzymes which causes rapid death of the organism, especially at lower temperatures which may occur on transport of the specimen to the laboratory. Similarly, Gram staining the CSF also has poor sensitivity (approximately 40%) when prior antibiotic treatment has been administered.

Immunological tests, such as particle latex agglutination, directly on the CSF sample has traditionally been a useful adjunct to the diagnosis of ABM when there are abnormal findings on CSF microscopy and chemistry. Blood stained CSF may however cause false-positive results on the latex agglutination test. Studies have shown that the latex agglutination test has a low sensitivity in patients who have received any antibiotics prior to sampling. However, Cryptococcal antigen testing continues to be the diagnostic standard for diagnosis of Cryptococcal meningitis.



Lancet Laboratories Limited Conservation House - 2nd Floor Along Ali Hassan Mwinyi Road Tel: +255 752 816 904 Email: info@lancet.co.tz www.cerbalancetafrica.co.tz. P.O Box 105894 Dar es Salaam, Tanzania www.cerbalancetafrica.co.tz. customer service.tanzania@lancet.co.tz



PCR detection methods are more sensitive than conventional culture or immunological latex antigen tests, and may detect organisms that are nonviable or unculturable. CSF is normally a sterile body site where any evidence of a micro-organism is likely to represent infection, and infections are typically monomicrobial. For these reasons, molecular methods are well suited for the diagnosis of CNS infections. The risks of contamination necessitate the need for strict adherence to aseptic collection policies (e.g. the use of sterile gloves and a surgical mask) during the LP procedure. Individuals with active respiratory infections (rhinovirus may cross-react with enterovirus), active/latent herpes simplex virus infection (i.e. cold sores), and asymptomatic shedders of S. pneumoniae, H. influenzae or other organisms, may contaminate samples and thus cause false-positive results. PCR panels that include detection of cytomegalovirus (CMV) and human herpesvirus-6 (HHV-6) do not distinguish between latent/chromosomally integrated, secondary reactivation, or active infections - positive results should be carefully interpreted in conjunction with other clinical, laboratory, and epidemiological information.

A negative PCR result does not exclude the possibility of CNS infection and should not be used as the sole basis for diagnosis, treatment, or other management decisions. There is a risk of false-negative results due to the presence of sequence variants or rearrangements in the gene targets of the assay, procedural errors,

inhibitors in specimens, technical error, sample mix-up, low pathogen load, or infection caused by an organism not detected by the panel used. Low viral load in CSF for certain viruses (e.g. herpes simplex virus), especially in the first 3 days after symptom onset, may warrant additional testing with an alternative singleplex assay, testing alternate sources (e.g. blood) or repeating the LP procedure after a few days for follow-up testing.

Lancet Laboratories offers both bacterial and viral PCR panels to provide the most sensitive test methodology and thus the most useful result for the management of your patients with meningitis /encephalitis. The bacterial PCR detects the most common causes of communityacquired

bacterial meningitis, including Listeria monocytogenes which is unavailable as a latex

agglutination test. The main limitations of bacterial PCR testing are that not all organisms are

included in the test, and antibiotic sensitivity is not yet done with molecular testing. Therefore, culture of the CSF with sensitivity testing should remain a part of the testing algorithm. Bacterial PCR testing will replace the latex agglutination (bacterial antigen) test. Viral PCR testing will only be performed if requested specifically.

Table 3. Organisms included in the **Multiplex PCR panels**

Bacterial multiplex PCR

Neisseria meningitidis	
Haemophilus influenzae	
Streptococcus pneumoniae	
Streptococcus agalactiae	
(group B strep)	
Listeria monocytogenes	
Escherichia coli K1	

Viral multiplex PCR

Herpes simplex type 1 Human herpesvirus 7 Herpes simplex type 2 Enterovirus Varicella zoster virus Parechovirus Cytomegalovirus Mumps virus Epstein-Barr virus Adenovirus Human herpesvirus 6

Mortality rates of ABM are still high, as much as 5% - 10%, despite intensive care and antibiotic therapy. The risk of neurologic sequelae in survivors of ABM is reported to be 20%. ABM is a medical emergency and molecular testing has a dramatic impact on diagnosis and management, whereby rapid identification of a pathogen can result in prompt initiation of appropriate antibiotics, which is life-saving.

References

- 1. Centres for Disease Control and Prevention and World Health Organisation Centres for Disease Control and Prevention and World Health Organisation. Laboratory methods for the diagnosis of meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae. WHO manual, second edition (2011). Available at: https://www.cdc.gov/meningitis/lab-manual/full-manual.pdf (Accessed August 2019.)
 Van de Beek D, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect 2016; 22(Suppl 3): S37 – 62.
 Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev 2010; 23(3): 467 – 492.
 Babr MC, and Boulware DR. Methods of ranid diagnosis for the etiology of

- 23(3): 467 492.
 4. Bahr NC and Boulware DR. Methods of rapid diagnosis for the etiology of meningitis in adults. Biomark Med 2014; 8(9): 1085 1103.
 5. Solomon T, Hart IJ, Beeching NJ. Viral encephalitis: a clinician's guide. Prac Neurol 2007; 7(5): 288 305.
 6. Kumar R. Aseptic Meningitis: diagnosis and management. Indian J Pediatr 2005; 72(1): 57 63.
 7. Mohammadi SF, et al. Diagnostic value of latex agglutination test in diagnosis of acute bacterial meningitis. Ann Indian Acad Neurol 2013; 16(4): 645 649.
 6. Tacon Cl. and Elower O. Diagnosis and management of hacterial meningitis.
- 645 649. 8. Tacon CL and Flower O. Diagnosis and management of bacterial meningitis in the paediatric population: a review. Emerg Med Int 2012; 2012:320309. doi: 10.1155/2012/320309.

- 9. Baspinar EO, et al. Comparison of culture and PCR methods in the diagnosis if bacterial meningitis. Braz J Microbiol 2017; 48(2): 322 236.
 10. Petti CA and Polage RP. Molecular diagnosis of central nervous system infections. In UpToDate. Tunkel AR and Sullivan M (Editors) (Accessed August 2019).
 11. Witton Park in association with the World Health Organisation and the Meningitis Research Foundation. Defeating meningitis by 2030 developing a global roadmap. Wednesday 27 February Friday 1 March 2019 | WP1675. Available at: https://www.wittonpark.org.uk/wp-content/uploads/WP1675-Report-pdf (Accessed August 2019).
 12. Smith AM, et al. Outbreak of Listeria monocytogenes in South Africa, 2017-2018: Laboratory activities and experiences associated with whole-genome sequencing analysis of isolates. Foodborne Pathog Dis 2019, 16(7): 524 530.
 13. Department of Health. Expanded programme on immunisation EPI (SA). Revised childhood immunisation schedule from April 2009. Available at: http://www.health.gov.za/index.phg/shortcodes/2015-03-29-10-42-47/2015-04-30-08

-29-27/immunization/category/165-immunisation/download=489:child-immunisation-schedule (Accessed August 2019).



Lancet Laboratories Limited **Conservation House - 2nd Floor** Along Ali Hassan Mwinyi Road Tel: +255 752 816 904 Email: info@lancet.co.tz www.cerbalancetafrica.co.tz.

P.O Box 105894 Dar es Salaam, Tanzania www.cerbalancetafrica.co.tz. customer service.tanzania@lancet.co.tz